RecruitingNCT07284667
ACP-211 for depression that has not improved with antidepressants
About this title
Read the official source — NCT07284667Researchers are comparing ACP-211 and placebo to find out how the approaches affect depression symptoms in adults with depression.
Medication studyAges 18–65United States
Understand this study
What is this study about?
Researchers are comparing ACP-211 and placebo to find out how the approaches affect depression symptoms in adults with depression.
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
What will I do during this study?
Participants are randomly assigned to oral ACP-211 at one of two dose levels or a matching placebo (an inactive comparison treatment). The assigned capsules are taken twice a week; the registry record reviewed does not specify the overall treatment duration.
- Listed locations
- Birmingham and 27 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 14, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 153
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07284667
- Official title
Show the full official title
A Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of ACP-211 Monotherapy in Adults With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Recruitment & locations
RecruitingBirmingham · Chino · Glendale
24 more locations
- La Jolla
- Orange
- West Hills
- Denver
- Fort Myers
- Hollywood
- Largo
- Orlando
- Tampa
- West Palm Beach
- Watertown
- Worcester
- Flowood
- Saint Charles
- Lincoln
- Las Vegas
- Marlton
- Brooklyn
- Cary
- North Canton
- Houston
- Katy
- The Woodlands
- Salt Lake City
A listed location does not confirm current availability.
Questions about this study
What is this study about?
Researchers are comparing ACP-211 and placebo to find out how the approaches affect depression symptoms in adults with depression.
Who is behind this study?
The study sponsor is ACADIA Pharmaceuticals Inc.
Does this study involve medication?
Yes. The study involves medication, including ACP-211 and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
